• Kyowa Kirin’s FY26 January-September core operating profit jumped 47% year over year to JPY 97 billion.
• Revenue rose 10% to JPY 384.9 billion, supported by North American growth, higher tech-licensing income and favorable foreign exchange.
• The drugmaker reached a voluntary U.S. government agreement to lower medicine costs, including discounts for certain medicines offered to state Medicaid patients.
• FY26 core operating profit guidance remained JPY 130 billion, with potential to exceed the plan supported by favorable foreign exchange.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.